Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Folia Histochemica et Cytobiologica
MENU
Shortcuts Submit an article Author Guidelines Ahead of Print Reviewers 2023 Editorial Board

open access

Vol 60, No 3 (2022)
Original paper
Submitted: 2021-12-06
Accepted: 2022-06-22
Published online: 2022-07-06
View PDF Download PDF file
Get Citation

Celastrol alleviates murine lupus nephritis via inducting CD4+Foxp3+ regulatory T cells

Guangbo Xiang1, Kai Shi2, Jinjun Wang3
DOI: 10.5603/FHC.a2022.0020
·
Pubmed: 35792673
·
Folia Histochem Cytobiol 2022;60(3):237-246.
Affiliations
  1. Department of Rheumatology and Immunology, Wenzhou Central Hospital, Wenzhou 325000, Zhejiang, China
  2. Department of Rehabilitation Medicine, The Second Hospital of Huangshi, Huangshi 435000, Hubei, China
  3. Department of Rheumatism and Acupuncture, Wuhan Hospital of Traditional Chinese Medicine, Wuhan 430000, Hubei, China

open access

Vol 60, No 3 (2022)
ORIGINAL PAPERS
Submitted: 2021-12-06
Accepted: 2022-06-22
Published online: 2022-07-06

Abstract

Introduction. Lupus nephritis (LN) is an autoimmune glomerulonephritis secondary to systemic lupus erythematosus. Commonly, immunosuppressive agents are required for treating LN. However, frequent use of conventional immunosuppressants may produce a variety of side effects. Hence, seeking alternative drugs for treating LN is very important. This report aims to figure out the immunoregulatory efficacy of celastrol (CLT) in LN.
Material and methods. A spontaneous in vivo model of LN was established in FasL-deficient B6/gld mice. ELISA was used for analyzing serum creatinine (Scr) and anti-dsDNA levels in mice. IHC staining, immunofluorescence and hematoxylin-eosin and PAS staining were applied to determine renal immunopathology and histology. Cytokine gene levels were assessed using RT qPCR. CD4+Foxp3+ Treg frequency in murine kidneys, lymph nodes and spleens was determined using flow cytometry analysis.
Results. CLT treatment alleviated renal dysfunction and renal injury in LN-prone B6/gld mice. Moreover, CLT reduced CD3+ T cell infiltration and inhibited proinflammatory cytokine expression in renal tissues of B6/gld mice. Importantly, CLT enhanced CD4+FoxP3+ Treg frequency in kidneys, lymph nodes and spleens of B6/gld mice.
Conclusions. CLT exerts therapeutic effects on murine LN by improving renal function and immunopathology and inducing CD4+FoxP3+ Tregs.

Abstract

Introduction. Lupus nephritis (LN) is an autoimmune glomerulonephritis secondary to systemic lupus erythematosus. Commonly, immunosuppressive agents are required for treating LN. However, frequent use of conventional immunosuppressants may produce a variety of side effects. Hence, seeking alternative drugs for treating LN is very important. This report aims to figure out the immunoregulatory efficacy of celastrol (CLT) in LN.
Material and methods. A spontaneous in vivo model of LN was established in FasL-deficient B6/gld mice. ELISA was used for analyzing serum creatinine (Scr) and anti-dsDNA levels in mice. IHC staining, immunofluorescence and hematoxylin-eosin and PAS staining were applied to determine renal immunopathology and histology. Cytokine gene levels were assessed using RT qPCR. CD4+Foxp3+ Treg frequency in murine kidneys, lymph nodes and spleens was determined using flow cytometry analysis.
Results. CLT treatment alleviated renal dysfunction and renal injury in LN-prone B6/gld mice. Moreover, CLT reduced CD3+ T cell infiltration and inhibited proinflammatory cytokine expression in renal tissues of B6/gld mice. Importantly, CLT enhanced CD4+FoxP3+ Treg frequency in kidneys, lymph nodes and spleens of B6/gld mice.
Conclusions. CLT exerts therapeutic effects on murine LN by improving renal function and immunopathology and inducing CD4+FoxP3+ Tregs.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

B6/gld mice; lupus nephritis; celastrol; CD4+FoxP3+ cells; kidney damage; cytokine gene expression

About this article
Title

Celastrol alleviates murine lupus nephritis via inducting CD4+Foxp3+ regulatory T cells

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 60, No 3 (2022)

Article type

Original paper

Pages

237-246

Published online

2022-07-06

Page views

4515

Article views/downloads

634

DOI

10.5603/FHC.a2022.0020

Pubmed

35792673

Bibliographic record

Folia Histochem Cytobiol 2022;60(3):237-246.

Keywords

B6/gld mice
lupus nephritis
celastrol
CD4+FoxP3+ cells
kidney damage
cytokine gene expression

Authors

Guangbo Xiang
Kai Shi
Jinjun Wang

References (49)
  1. Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. 2020; 172(11): ITC81–ITC96.
    CrossRefPubMed
  2. Chang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Curr Opin Rheumatol. 2021; 33(2): 197–204.
    CrossRefPubMed
  3. Aljaberi N, Bennett M, Brunner HI, et al. Proteomic profiling of urine: implications for lupus nephritis. Expert Rev Proteomics. 2019; 16(4): 303–313.
    CrossRefPubMed
  4. Ma HY, Chen S, Cao WD, et al. Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Ren Fail. 2021; 43(1): 20–31.
    CrossRefPubMed
  5. Zhao Y, Hu W, Chen P, et al. Immunosuppressive and metabolic agents that influence allo- and xenograft survival by in vivo expansion of T regulatory cells. Xenotransplantation. 2020; 27(6): e12640.
    CrossRefPubMed
  6. Xia Y, Fang X, Dai X, et al. Iguratimod ameliorates nephritis by modulating the Th17/Treg paradigm in pristane-induced lupus. Int Immunopharmacol. 2021; 96: 107563.
    CrossRefPubMed
  7. Zhao M, Shao Y, Xu J, et al. LINC00466 impacts cell proliferation, metastasis and sensitivity to temozolomide of glioma by sponging miR-137 to regulate PPP1R14B expression. Onco Targets Ther. 2021; 14: 1147–1159.
    CrossRefPubMed
  8. Aziz F, Chaudhary K. Lupus nephritis: a treatment update. Curr Clin Pharmacol. 2018; 13(1): 4–13.
    CrossRefPubMed
  9. Allison AC, Cacabelos R, Lombardi VR, et al. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25(7): 1341–1357.
    CrossRefPubMed
  10. Venkatesha SH, Yu H, Rajaiah R, et al. Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. J Biol Chem. 2011; 286(17): 15138–15146.
    CrossRefPubMed
  11. Lee JH, Choi KJ, Seo WD, et al. Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90. Int J Mol Med. 2011; 27(3): 441–446.
    CrossRefPubMed
  12. Zhang X, Yang J, Chen M, et al. Metabolomics profiles delineate uridine deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human acute promyelocytic leukemia cells. Oncotarget. 2016; 7(29): 46557–46572.
    CrossRefPubMed
  13. Shaker ME, Ashamallah SA, Houssen ME. Celastrol ameliorates murine colitis via modulating oxidative stress, inflammatory cytokines and intestinal homeostasis. Chem Biol Interact. 2014; 210: 26–33.
    CrossRefPubMed
  14. Venkatesha SH, Dudics S, Astry B, et al. Control of autoimmune inflammation by celastrol, a natural triterpenoid. Pathog Dis. 2016; 74(6).
    CrossRefPubMed
  15. Guo L, Luo S, Du Z, et al. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis. Nat Commun. 2017; 8(1): 878.
    CrossRefPubMed
  16. Xu X, Zhong J, Wu Z, et al. Effects of tripterine on mRNA expression of TGF-beta1 and collagen IV expression in BW F1 mice. Cell Biochem Funct. 2007; 25(5): 501–507.
    CrossRefPubMed
  17. Li H, Zhang Yy, Huang XY, et al. Beneficial effect of tripterine on systemic lupus erythematosus induced by active chromatin in BALB/c mice. Eur J Pharmacol. 2005; 512(2-3): 231–237.
    CrossRefPubMed
  18. Chu C, He W, Kuang Y, et al. Celastrol protects kidney against ischemia-reperfusion-induced injury in rats. J Surg Res. 2014; 186(1): 398–407.
    CrossRefPubMed
  19. Zhang J, Shan J, Chen X, et al. Celastrol mediates Th17 and Treg cell generation via metabolic signaling. Biochem Biophys Res Commun. 2018; 497(3): 883–889.
    CrossRefPubMed
  20. Wang Y, Cao Lu, Xu LM, et al. Celastrol ameliorates EAE induction by suppressing pathogenic T cell responses in the peripheral and central nervous systems. J Neuroimmune Pharmacol. 2015; 10(3): 506–516.
    CrossRefPubMed
  21. Astry B, Venkatesha SH, Laurence A, et al. Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ. Clin Immunol. 2015; 157(2): 228–238.
    CrossRefPubMed
  22. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994; 76(6): 969–976.
    CrossRefPubMed
  23. Liang CL, Lu W, Zhou JY, et al. Mangiferin attenuates murine lupus nephritis by inducing CD4+Foxp3+ regulatory T cells via suppression of mTOR signaling. Cell Physiol Biochem. 2018; 50(4): 1560–1573.
    CrossRefPubMed
  24. Costa-Bauza A, Grases F, Gomila I, et al. A simple and rapid colorimetric method for determination of phytate in urine. Urol Res. 2012; 40(6): 663–669.
    CrossRefPubMed
  25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402–408.
    CrossRefPubMed
  26. Martin-Moreno PL, Tripathi S, Chandraker A. Regulatory T cells and kidney transplantation. Clin J Am Soc Nephrol. 2018; 13(11): 1760–1764.
    CrossRefPubMed
  27. Hou X, Song J, Su J, et al. CD4(+)Foxp3(+) Tregs protect against innate immune cell-mediated fulminant hepatitis in mice. Mol Immunol. 2015; 63(2): 420–427.
    CrossRefPubMed
  28. Kronbichler A, Brezina B, Gauckler P, et al. Refractory lupus nephritis: When, why and how to treat. Autoimmun Rev. 2019; 18(5): 510–518.
    CrossRefPubMed
  29. Wang S, Chen D, Zuo Ke, et al. Long-term renal outcomes of mesangial proliferative lupus nephritis in Chinese patients. Clin Rheumatol. 2022; 41(2): 429–436.
    CrossRefPubMed
  30. Chen J, Wu W, Zhang M, et al. Taraxasterol suppresses inflammation in IL-1β-induced rheumatoid arthritis fibroblast-like synoviocytes and rheumatoid arthritis progression in mice. Int Immunopharmacol. 2019; 70: 274–283.
    CrossRefPubMed
  31. Zhao P, Su G, Xiao X, et al. Chinese medicinal herb Radix Astragali suppresses cardiac contractile dysfunction and inflammation in a rat model of autoimmune myocarditis. Toxicol Lett. 2008; 182(1-3): 29–35.
    CrossRefPubMed
  32. Luo Y, Zhang Y, Kuai Le, et al. Efficacy and safety of Tripterygium glycosides in Sjögren's syndrome treatment: evidence from 12 randomized controlled trials. Ann Palliat Med. 2021; 10(7): 8215–8231.
    CrossRefPubMed
  33. An L, Li Z, Shi L, et al. Inflammation-targeted celastrol nanodrug attenuates collagen-induced arthritis through nf-κb and notch1 pathways. Nano Lett. 2020; 20(10): 7728–7736.
    CrossRefPubMed
  34. Liu Y, Xiao N, Du H, et al. Celastrol ameliorates autoimmune disorders in Trex1-deficient mice. Biochem Pharmacol. 2020; 178: 114090.
    CrossRefPubMed
  35. Lu Y, Liu Y, Zhou J, et al. Biosynthesis, total synthesis, structural modifications, bioactivity, and mechanism of action of the quinone-methide triterpenoid celastrol. Med Res Rev. 2021; 41(2): 1022–1060.
    CrossRefPubMed
  36. Lagoa R, Silva J, Rodrigues JR, et al. Advances in phytochemical delivery systems for improved anticancer activity. Biotechnol Adv. 2020; 38: 107382.
    CrossRefPubMed
  37. Abdin AA, Hasby EA. Modulatory effect of celastrol on Th1/Th2 cytokines profile, TLR2 and CD3+ T-lymphocyte expression in a relapsing-remitting model of multiple sclerosis in rats. Eur J Pharmacol. 2014; 742: 102–112.
    CrossRefPubMed
  38. Yang H, Liu C, Jiang J, et al. Celastrol attenuates multiple sclerosis and optic neuritis in an experimental autoimmune encephalomyelitis model. Front Pharmacol. 2017; 8: 44.
    CrossRefPubMed
  39. Qi WH, Zhang YY, Xing K, et al. 2', 4'-Dihydroxy-2,3-dimethoxychalcone: A pharmacological inverse agonist of RORγt ameliorating Th17-driven inflammatory diseases by regulating Th17/Treg. Int Immunopharmacol. 2022; 108: 108769.
    CrossRefPubMed
  40. Honda M, Segawa T, Ishikawa K, et al. Nephronectin influences EAE development by regulating the Th17/Treg balance via reactive oxygen species. Am J Physiol Cell Physiol. 2022; 322(4): C699–C711.
    CrossRefPubMed
  41. Zhou F, Wang X, Wang L, et al. Genetics, epigenetics, cellular immunology, and gut microbiota: emerging links with graves' disease. Front Cell Dev Biol. 2021; 9: 794912.
    CrossRefPubMed
  42. Nie Y, Fu C, Zhang H, et al. Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway. BMC Complement Med Ther. 2020; 20(1): 321.
    CrossRefPubMed
  43. Hu X, Jia M, Fu Yu, et al. Novel low-toxic derivative of celastrol maintains protective effect against acute renal injury. ACS Omega. 2018; 3(3): 2652–2660.
    CrossRefPubMed
  44. Alahyari S, Rajaeinejad M, Jalaeikhoo H, et al. Regulatory T cells in immunopathogenesis and severity of COVID-19: a systematic review. Arch Iran Med. 2022; 25(2): 127–132.
    CrossRefPubMed
  45. Esensten JH, Muller YD, Bluestone JA, et al. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier. J Allergy Clin Immunol. 2018; 142(6): 1710–1718.
    CrossRefPubMed
  46. Yan JJ, Lee JG, Jang JY, et al. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4CD25Foxp3 regulatory T cells. Kidney Int. 2017; 91(3): 603–615.
    CrossRefPubMed
  47. Matta MC, Soares DC, Kerstenetzky MS, et al. CD4+CD25 high foxp3+ treg deficiency in a Brazilian patient with gaucher disease and lupus nephritis. Hum Immunol. 2016; 77(2): 196–200.
    CrossRefPubMed
  48. Afeltra A, Gigante A, Margiotta DP, et al. The involvement of T regulatory lymphocytes in a cohort of lupus nephritis patients: a pilot study. Intern Emerg Med. 2015; 10(6): 677–683.
    CrossRefPubMed
  49. Liang CL, Lu W, Qiu F, et al. Paeoniflorin ameliorates murine lupus nephritis by increasing CD4+Foxp3+ Treg cells via enhancing mTNFα-TNFR2 pathway. Biochem Pharmacol. 2021; 185: 114434.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl